About Us
OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in March of 2017.
Technology
OncoTartis is exploring a proprietary drug discovery approach called “TARTIS” (TARTIS = TARgeting TISsue). TARTIS is designed to develop small molecules for treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organism (i.e., gender-associated tissues or melanocytes) or can be effectively replaced (hematopoietic system). TARTIS technology involves screening of chemical and/or shRNA libraries for identification of small molecules and shRNAs corresponding to specific genes, which are capable of selective killing of cells representing the tissue of choice.
Pipeline
An anti-AML candidate, OT-82, has a favorable set of structural, ADME and toxicological properties. A broad composition of matter patent application was filed in December of 2013. OT-82 is an orally available NAMPT (NicotinAMide Phosphoribosyl Transferase) inhibitor. Found as a compound largely selective towards haematological malignancies, OT-82 is efficatious against broad range of leukemias and lymphomas.
OT-82 program has completed in vivo and ex vivo efficacy studies, developed CMC package and produced a kilo-scale batch for IND-enabling studies. Formal toxicology studies have been successfully completed in Russia and GLP tox studies will be completed in 4Q16. IND is expected to be filed in 1Q 2017.
OT-82 program has completed in vivo and ex vivo efficacy studies, developed CMC package and produced a kilo-scale batch for IND-enabling studies. Formal toxicology studies have been successfully completed in Russia and GLP tox studies will be completed in 4Q16. IND is expected to be filed in 1Q 2017.